RSS-Feed abonnieren
DOI: 10.1055/s-2005-918182
© Georg Thieme Verlag Stuttgart · New York
Welche Form der Nachsorge ist bei Patienten mit R0-resezierten gastrointestinalen Stromatumoren (GIST) sinnvoll?
How Should Patients with Completely Resected Gastrointestinal Stromal Tumours (GIST) be Followed Up?Publikationsverlauf
Publikationsdatum:
29. Dezember 2005 (online)
![](https://www.thieme-connect.de/media/zblchir/200506/lookinside/thumbnails/10.1055-s-2005-918182-1.jpg)
Zusammenfassung
Gastrointestinale Stromatumoren (GIST) sind aufgrund ihres unsicheren biologischen Verhaltens und der durch Imatinib gegebenen Therapieoption von aktuellem Interesse. In der folgenden Studie soll untersucht werden, welche Form der Nachsorge zur Erkennung eines Rezidives geeignet und ökonomisch vertretbar ist. Patienten und Methode: Wir behandelten im Zeitraum von 07/97 bis 02/04 43 GIST-Patienten. Bei Vorliegen eines hohen (HR) oder intermediären Risikos (IR) bzw. nachgewiesener Malignität (OM) wurde ein regelmäßiges Follow-up durchgeführt. Anfang 2004 untersuchten wir alle Patienten unabhängig von der Risikokonstellation nach. Neben einer Abdomensonographie führten wir bei zugänglichem Ursprungsorgan eine Endoskopie und eine Endosonographie durch. Eine weiterführende Diagnostik erfolgte befundabhängig. Ergebnisse: Bei 33 Patienten unter Risiko traten fünf Rezidive auf. Die Konstellation hinsichtlich malignen Verhaltens der rezidivierten Tumoren laut Einteilung des NIH war: 2 × OM, 1 × HR, 2 × IR. Das Intervall zwischen Erstbehandlung und Auftreten eines Rezidives lag bei 4,5 bis 33 Monaten. Vier der rezidivierten Patienten wurden mit Imatinib therapiert, der fünfte Patient wurde vor der Imatinib-Ära palliativ behandelt. Schlussfolgerung: Nach unserer Erfahrung sollte eine strukturierte Nachsorge nur bei Patienten mit OM, HR und IR GIST in den ersten zwei Jahren alle 6 Monate, dann jährlich für weitere drei Jahre durchgeführt werden.
Abstract
Gastrointestinal stromal tumours are topical because of their uncertain biological behaviour and the potential of treatment with imatinib. In the following study we have examined which pattern of follow-up is both appropriate for detecting recurrences and cost-effective. Patients and methods: Between July 1997 and February 2004 we treated 43 patients diagnosed with a GIST. Patients with high risk (HR), intermediate risk (IR), or overtly malignant (OM) tumours were followed-up regularly. In 2004 we screened all patients independent of their risk of malignant disease with an ultrasound scan and endoscopy followed by endosonography. Further diagnostic procedures were carried out if necessary. Results: Overall, we diagnosed recurrences in five out of 33 patients at risk (two in patients with OM, one in a patient with HR, and 2 in patients with IR according to the NIH criteria). The time period between resection of the primary tumour and recurrence ranged from 4.5 to 33 months. One of the patients with a recurrence was seen before the imatinib era, the other four were treated with imatinib mesylate. Conclusion: In our experience, regular follow-up should be restricted to patients with OM, HR, and IR GIST. We suggest that patients are initially seen in six months intervals for two years and annually for another three years thereafter.
Schlüsselwörter
GIST - Nachsorge - Rezidiv - Imatinib
Key words
GIST - follow-up - recurrence - imatinib mesylate
Literatur
- 1 Bucher P, Taylor S, Villiger P, Morel P, Brundler M A. Are there any prognostic factors for small intestinal stromal tumors?. Am J Surg. 2004; 187 761-766
- 2 Bümming P, Andersson J, Meis-Kindblom J M, Klingenstierna H, Engström K, Stierner U, Wängberg B, Jansson S, Ahlman H, Kindblom L G, Nilsson B. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer. 2003; 89 460-464
- 3 Cormier J N, Patel S R, Pisters P WT. Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib. Curr Oncol Rep. 2002; 4 504-509
- 4 Crosby J A, Catton C N, Davis A, Couture J, O'Sullivan B, Kandel R, Swallow C J. Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol. 2001; 8 50-59
- 5 Davila R E, Faigel D O. GI stromal tumors. Gastrointest Endosc. 2003; 58 80-88
- 6 DeMatteo R P. The GIST of targeted cancer therapy: a tumor (Gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571). Ann Surg Oncol. 2002; 9 831-839
- 7 DeMatteo R P, Heinrich M C, El-Rifai W M, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002; 33 466-477
- 8 DeMatteo R P, Lewis J J, Leung D, Mudan S S, Woodruff J M, Brennan M F. Two hundred gastrointestinal stromal tumors. Recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231 51-58
- 9 Demetri G D, Baker L H, Beech D, Benjamin R. et al .Practice guidelines in oncology: gastrointestinal stromal tumors (GIST). 2004; www.nccn.org/physician_gls/f_guidelines.html
- 10 Demetri G D, Mehren M, Blanke C D, van den Abbeele A D, Eisenberg B, Roberts P J, Heinrich M C, Tuveson D A, Singer S, Janicek M, Fletcher J A, Silverman S G, Silberman S L, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker B J, Corless C, Fletcher C DM, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347 472-480
- 11 Emory T S, Sobin L H, Lukes L, Lee D H, O'Leary T J. Prognosis of gastrointestinal smooth-muscle (stromal) tumors. Dependence on anatomic site. Am J Surg Pathol. 1999; 23 82-87
- 12 Evans H L. Smooth muscle tumors of the gastrointestinal tract. A study of 56 cases followed for a minimum of 10 years. Cancer. 1985; 56 2242-2250
- 13 Fletcher C DM, Berman J J, Corless C, Gorstein F, Lasota J, Longley B J, Miettinen M, O'Leary T J, Remotti H, Rubin B P, Shmookler B, Sobin L H, Weiss S W. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002; 33 459-465
- 14 Franquemont D W. Differentiation and risk assessment of gastrointestinal stromal tumors. Am J Clin Pathol. 1995; 103 41-47
- 15 Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumor: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade. Hum Pathol. 2002; 33 669-676
- 16 Hermanek P, Junginger T, Hossfeld D K, Müller R P, Fölsch U R. Nachsorge und Rehabilitation bei Patienten mit gastrointestinalen Tumoren. Dtsch Ärztebl. 1999; 96 A 2084-2088
- 17 Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Tunio G M, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279 577-580
- 18 Hohenberger P. Neue Konzepte der chirurgischen Therapie gastrointestinaler Stromatumoren (GIST). Viszeralchirurgie. 2003; 38 379-386
- 19 Kim C J, Day S, Yeh K A. Gastrointestinal stromal tumors: analysis of clinical and pathologic factors. Am Surg. 2001; 67 135-137
- 20 Lehnert T. Gastrointestinal sarcoma (GIST) - a review of surgical management. Ann Chir Gynaecol. 1998; 87 297-305
- 21 Mechtersheimer G, Egerer G, Hensel M, Rieker R J, Libicher M, Lehnert T, Penzel R. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch. 2004; 444 108-118
- 22 Miettinen M, Blay J Y, Sobin L H. Mesenchymal tumours of the stomach. In: Hammilton SR, Aaltonen LA (eds.). World Health Organization classification of tumours. Pathology and genetics of the digestive system. IARC Press, Lyon 2000; 62-65
- 23 Miettinen M, El-Rifai W, Sobin L H, Lasota J. Evaluation of gastrointestinal stromal tumors: a review. Hum Pathol. 2002; 33 478-483
- 24 Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin L H, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus. A clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases. Am J Surg Pathol. 2001; 25 1121-1133
- 25 Miettinen M, Kopczynski J, Makhlouf H R, Sarlomo-Rikala M, Gyorffy H, Burke A, Sobin L H, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum. A clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases. Am J Surg Pathol. 2003; 27 625-641
- 26 Miettinen M, Sarlomo-Rikala M, Sobin L H, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon. A clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases. Am J Surg Pathol. 2000; 24 1339-1352
- 27 Mudan S S, Conlon K C, Woodruff J M, Lewis J J, Brennan M F. Salvage surgery for patients with recurrent gastrointestinal sarcoma: Prognostic factors to guide patient selection. Cancer. 2000; 88 66-74
- 28 Ng E H, Pollock R E, Munsell M F, Atkinson E N, Romsdahl M M. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg. 1992; 215 68-77
- 29 Pierie J P, Choudry U, Muzikansky A, Yeap B Y, Souba W W, Ott M J. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg. 2001; 136 383-389
- 30 Reith J D, Goldblum J R, Lyles R H, Weiss S W. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol. 2000; 13 577-585
- 31 Samiian L, Weaver M, Velanovich V. Evaluation of gastrointestinal stromal tumors for recurrence rates and patterns of long-term follow-up. Am Surg. 2004; 70 187-191
- 32 Sarlomo-Rikala M, Kovatich A J, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998; 11 728-734
- 33 Scaife C L, Hunt K K, Patel S R, Benjamin R S, Burgess M A, Chen L L, Trent J, Raymond A K, Cormier J N, Pisters P WT, Pollock R E, Feig B W. Is there a role for surgery in patients with “unresectable” cKIT + gastrointestinal stromal tumors treated with imatinib mesylate?. Am J Surg. 2003; 186 665-669
- 34 Singer S, Rubin B P, Lux M L, Chen C J, Demetri G D, Fletcher C DM, Fletcher J A. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol. 2002; 20 3898-3905
- 35 van Oosterom A T, Judson I, Verweij J, Stroobants S, diPaola E D, Dimitrijevic S, Martens M, Webb A, Sciot R, van Glabbeke M, Silberman S, Nielsen O S. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001; 358 1421-1423
- 36 Wong N ACS, Young R, Malcomson R DG, Nayar A G, Jamieson L A, Save V E, Carey F A, Brewster D H, Han C, Al-Nafussi A. Prognostic indicators for gastrointestinal stromal tumors: a clinicopathological and immunohistochemical study of 108 resected cases of the stomach. Histopathology. 2003; 43 118-126
- 37 Wu P C, Langerman A, Ryan C W, Hart J, Swiger S, Posner M C. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era. Surgery. 2003; 134 656-665
- 38 Yan H, Marchettini P, Acherman Y IZ, Gething S A, Brun E, Sugarbaker P H. Prognostic assessment of gastrointestinal stromal tumor. Am J Clin Oncol. 2003; 26 221-228
Dr. med. S. Stelzner
Krankenhaus Dresden-Friedrichstadt · Städtisches Klinikum · Klinik für Allgemein- und Abdominalchirurgie
Friedrichstr. 41
01067 Dresden
Telefon: 0351/4 80 15 20
Fax: 0351/4 80 11 49
eMail: Stelzner-Si@khdf.de